Business Context and Reporting Period
NanoViricides, Inc. filed a Form 8-K on September 3, 2013, reporting a corporate action effective September 10, 2013. The company, incorporated in Nevada, is based in West Haven, Connecticut.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
The company executed a reverse stock split on a 1-for-3.5 basis. This action was taken to meet listing requirements for a national securities exchange. The Board of Directors unanimously approved the amendment to the Articles of Incorporation.
- Authorized Common Stock: Reduced to 85,714,286 shares.
- Authorized Preferred Stock: Reduced to 5,714,286 shares (blank check).
- Outstanding Common Stock: Approximately 46,854,239 shares.
- Outstanding Preferred Stock: Approximately 2,820,572 shares.
Guidance, Outlook, and Risks
The filing provides no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies beyond the strategic intent to qualify for exchange listing. No unusual items were reported.
Investor Verification Checklist
- Confirm the effective date of the reverse stock split (September 10, 2013) and its impact on share ownership.
- Verify the new authorized and outstanding share counts post-split.
- Review the attached Exhibit 3.1 (Certificate of Change) for legal specifics of the amendment.
- Check subsequent filings to confirm if the stock successfully qualified for listing on a national securities exchange.